• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

伴有复杂核型的慢性淋巴细胞白血病患者的管理策略

Management strategies for patients with chronic lymphocytic leukaemia harbouring complex karyotype.

作者信息

Serafin Andrea, Ruocco Valeria, Cellini Alessandro, Angotzi Francesco, Bonaldi Laura, Trentin Livio, Visentin Andrea

机构信息

Hematology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy.

Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, Padova, Italy.

出版信息

Br J Haematol. 2025 Mar;206(3):832-841. doi: 10.1111/bjh.19986. Epub 2025 Jan 6.

DOI:10.1111/bjh.19986
PMID:39761654
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11886947/
Abstract

Chronic lymphocytic leukaemia (CLL) is a heterogeneous disease characterised by the uncontrolled proliferation of mature lymphocytes. A subset of CLL patients harbouring complex karyotype (CK) presents with poor prognosis and limited treatment options. This review aims to discuss the current understanding of such patient subset, including its molecular landscape, diagnostic approaches, treatment modalities and emerging therapies. Furthermore, it outlines strategies for personalised management to improve clinical outcomes in this challenging patient population.

摘要

慢性淋巴细胞白血病（CLL）是一种异质性疾病，其特征为成熟淋巴细胞的不受控制增殖。一部分具有复杂核型（CK）的CLL患者预后较差且治疗选择有限。本综述旨在讨论对这类患者亚群的当前认识，包括其分子格局、诊断方法、治疗方式和新兴疗法。此外，还概述了个性化管理策略，以改善这一具有挑战性的患者群体的临床结局。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83ce/11886947/2a23198ab905/BJH-206-832-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83ce/11886947/5ae31205f1de/BJH-206-832-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83ce/11886947/2a23198ab905/BJH-206-832-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83ce/11886947/5ae31205f1de/BJH-206-832-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83ce/11886947/2a23198ab905/BJH-206-832-g003.jpg

相似文献

1
Management strategies for patients with chronic lymphocytic leukaemia harbouring complex karyotype.伴有复杂核型的慢性淋巴细胞白血病患者的管理策略
Br J Haematol. 2025 Mar;206(3):832-841. doi: 10.1111/bjh.19986. Epub 2025 Jan 6.
2
The importance of complex karyotype in prognostication and treatment of chronic lymphocytic leukemia (CLL): a comprehensive review of the literature.复杂核型在慢性淋巴细胞白血病（CLL）预后和治疗中的重要性：文献综述。
Leuk Lymphoma. 2019 Oct;60(10):2348-2355. doi: 10.1080/10428194.2019.1576038. Epub 2019 Feb 18.
3
Complex karyotype as a predictor of high-risk chronic lymphocytic leukemia: A single center experience over 12 years.复杂核型作为高危慢性淋巴细胞白血病的预测指标：12 年单中心经验。
Leuk Res. 2019 Oct;85:106218. doi: 10.1016/j.leukres.2019.106218. Epub 2019 Aug 16.
4
The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations.复杂核型与慢性淋巴细胞白血病：预后价值与诊断建议。
Am J Hematol. 2020 Nov;95(11):1361-1367. doi: 10.1002/ajh.25956. Epub 2020 Aug 28.
5
How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options.在新的治疗选择的浪潮中，如何为慢性淋巴细胞白血病选择最佳的治疗和检测方法。
Curr Oncol Rep. 2019 Jul 20;21(8):74. doi: 10.1007/s11912-019-0819-x.
6
Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax-based regimens.探讨基于维奈托克的方案治疗慢性淋巴细胞白血病患者中复杂核型的预后作用。
Br J Haematol. 2024 Jul;205(1):189-193. doi: 10.1111/bjh.19517. Epub 2024 May 6.
7
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.高核型复杂性是接受 venetoclax 联合治疗的 CLL 患者的独立预后因素。
Blood. 2023 Aug 3;142(5):446-459. doi: 10.1182/blood.2023019634.
8
Molecular pathogenesis of chronic lymphocytic leukaemia.慢性淋巴细胞白血病的分子发病机制。
Br J Haematol. 2019 Sep;186(5):668-684. doi: 10.1111/bjh.16102. Epub 2019 Jul 31.
9
BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.BCL-2 抑制作为慢性淋巴细胞白血病的治疗方法。
Curr Treat Options Oncol. 2021 Jun 10;22(8):66. doi: 10.1007/s11864-021-00862-z.
10
In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics.在伴有复杂核型的慢性淋巴细胞白血病中，主要的结构异常确定了一组预后较差且具有独特生物学特征的患者亚群。
Br J Haematol. 2018 Apr;181(2):229-233. doi: 10.1111/bjh.15174. Epub 2018 Apr 2.

本文引用的文献

1
ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia.欧洲肿瘤内科学会（ESMO）慢性淋巴细胞白血病一线及复发时新型靶向治疗的临床实践指南临时更新
Ann Oncol. 2024 Sep;35(9):762-768. doi: 10.1016/j.annonc.2024.06.016. Epub 2024 Jul 3.
2
Complex Karyotype Detection in Chronic Lymphocytic Leukemia: A Comparison of Parallel Cytogenetic Cultures Using TPA and IL2+DSP30 from a Single Center.慢性淋巴细胞白血病复杂核型检测：来自单一中心的使用TPA和IL2 + DSP30的平行细胞遗传学培养比较
Cancers (Basel). 2024 Jun 18;16(12):2258. doi: 10.3390/cancers16122258.
3
Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax-based regimens.
探讨基于维奈托克的方案治疗慢性淋巴细胞白血病患者中复杂核型的预后作用。
Br J Haematol. 2024 Jul;205(1):189-193. doi: 10.1111/bjh.19517. Epub 2024 May 6.
4
Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials.基于阿卡替尼的方案在一线或复发/难治性高风险 CLL 中的应用：5 项临床试验的汇总分析。
Blood Adv. 2024 Jul 9;8(13):3345-3359. doi: 10.1182/bloodadvances.2023011307.
5
Chromothripsis in hematologic malignancies.血液恶性肿瘤中的染色体重排
Exp Hematol. 2024 Apr;132:104172. doi: 10.1016/j.exphem.2024.104172. Epub 2024 Feb 1.
6
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.基于微小残留病灶评估的慢性淋巴细胞白血病治疗策略
N Engl J Med. 2024 Jan 25;390(4):326-337. doi: 10.1056/NEJMoa2310063. Epub 2023 Dec 10.
7
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.固定疗程伊布替尼-维奈托克对比苯丁酸氮芥-奥滨尤妥珠单抗治疗初治慢性淋巴细胞白血病（GLOW）：多中心、开放标签、随机、3 期临床试验的 4 年随访结果。
Lancet Oncol. 2023 Dec;24(12):1423-1433. doi: 10.1016/S1470-2045(23)00452-7. Epub 2023 Nov 6.
8
Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization.荧光原位杂交检测慢性淋巴细胞白血病伴CDKN2A/B缺失患者的特征及预后
Blood Adv. 2023 Dec 12;7(23):7239-7242. doi: 10.1182/bloodadvances.2023010753.
9
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.在慢性淋巴细胞白血病中使用共价 BTK 抑制剂后使用 pirtobrutinib。
N Engl J Med. 2023 Jul 6;389(1):33-44. doi: 10.1056/NEJMoa2300696.
10
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.西达基奥仑赛治疗慢性淋巴细胞白血病和小淋巴细胞淋巴瘤（TRANSCEND CLL 004）：一项多中心、开放标签、单臂、1-2 期研究。
Lancet. 2023 Aug 19;402(10402):641-654. doi: 10.1016/S0140-6736(23)01052-8. Epub 2023 Jun 6.